Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-09-17 Governance Information
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Governance Information Classification · 1% confidence The document is a press release dated September 17, 2015, announcing that Onxeo SA received the 'Gouvernance d'Argent' (Silver Governance) award for the second consecutive year. The text explicitly discusses the company's best practices in governance, board composition, transparency, and corporate functioning, referencing the criteria used by the AGEFI Grand Prix organizers, which are based on data from the annual report and reference document. Since the document is an announcement about receiving an award related to governance practices, it directly relates to the company's internal rules and board structure as recognized by an external body. This aligns best with the Governance Information category (CGR). It is not a full Annual Report (10-K), an Earnings Release (ER), or a specific management/board change announcement (MANG).
2015-09-17 French
Communicated under the obligation to provide permanent information / Other communications
Governance Information Classification · 1% confidence The document is a press release announcing that the company, Onxeo, received the 'Silver Governance' award from the financial magazine AGEFI. The text explicitly discusses the criteria for the award, which include 'composition of the companies' Board of Directors, the transparency of communication, the functioning of corporate bodies, social responsibility, and risk management.' These topics are central to corporate governance practices. While the award is based on data from annual reports and reference documents, the document itself is an announcement about a governance recognition, not the governance report (CGR) or the annual report (10-K) itself. Since the core subject matter is governance practices and awards related to them, the most fitting category is Governance Information (CGR), as it relates directly to the structure and practices being recognized, even though it's framed as an announcement. Given the specific focus on governance awards and practices, CGR is a better fit than the general Regulatory Filings (RNS).
2015-09-17 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 15, 2015, announcing that Onxeo SA has filed a patent application for its drug Livatag®. This announcement concerns intellectual property, product development, and potential commercial exclusivity extension. It is not a full annual report (10-K), an earnings release (ER), a quarterly report (IR), or a formal regulatory filing like a proxy statement (DEF 14A). Since the core subject is a specific corporate action related to intellectual property and product protection, it best fits under a general corporate announcement category. Given the options, it is a specific corporate update that doesn't fit the defined categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS). It is a specific announcement about a legal/IP asset. While 'LTR' (Legal Proceedings Report) is close, this is a proactive patent filing, not a report on litigation. The most appropriate general category for specific, non-financial, non-meeting related corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS) as a catch-all for significant corporate news releases, or potentially 'IP' if that were an option, but since it is not, RNS is the best fit for a press release detailing a patent filing.
2015-09-15 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated September 15, 2015, announcing that Onxeo S.A. has filed an international patent application for its product Livatag®. The content focuses on intellectual property (IP) protection, patent extension timelines, and clinical trial updates (ReLive study). This type of announcement, which details specific legal/IP actions or significant business developments outside of routine financial reporting (like earnings or annual reports), fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were about a lawsuit. Since it is a proactive filing announcement regarding IP, and RNS is the general regulatory announcement fallback, RNS is the most appropriate classification among the provided options, as it is not a specific financial report (10-K, IR, ER) or a management change (MANG). Given the focus on patent filing, it is a specific regulatory/legal update, but RNS serves as the best fit for general regulatory announcements not covered elsewhere.
2015-09-15 English
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release announcing that the company, Onxeo, will be presenting at an external investor event called 'InvestorDagen 2015'. It details the date, location, and the topics the CFO will cover, including company strengths, strategy, and product pipeline updates. This type of announcement, which informs investors about participation in a specific investor conference or presentation, is best classified as an Investor Presentation (IP) announcement or, given the context of informing about participation in an external event, it strongly aligns with materials shared in an investor context. Since it is an announcement about participation rather than the presentation slides themselves, and it focuses on strategy and pipeline for investors, 'Investor Presentation' (IP) is the most fitting category, although 'Regulatory Filings' (RNS) could be a fallback if the content were purely administrative. However, the content is clearly geared towards investor relations and strategy updates, making IP the primary choice.
2015-09-08 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document explicitly states in the title and first paragraph: "*Publication of a Shareholders Letter*" and "Onxeo S.A. ... today announces the publication of a Shareholders Letter(1).". It further clarifies that the letter updates on H1 2015 achievements and catalysts, and directs the reader to the website for the actual letter. Since the document is short (2820 chars) and serves primarily to announce the availability of another document (the Shareholders Letter), it fits the definition of a Report Publication Announcement (RPA). While 'Shareholders Letter' might suggest investor communication, the core action described is the *announcement of publication*, making RPA the most accurate classification based on the provided rules, especially Rule 2.
2015-09-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.